Sidley is representing CA Healthcare Acquisition Corp., a special purpose acquisition company focused on investing in a growth-oriented healthcare company, in its pending business combination with LumiraDx Limited, a next-generation point of care diagnostics testing company. The transaction has an implied pro forma equity value of US$5.1 billion.
Among other diagnostic solutions, LumiraDx has developed its high sensitivity antigen test for COVID-19 on the LumiraDx Platform. The test is currently being used by the National Health Service and Boots in the UK, CVS Health in the U.S., a significant number of accident and emergency rooms in Italy, and is being deployed in partnership with the Bill and Melinda Gates Foundation in a growing number of African countries where access to laboratory diagnostics is limited. The LumiraDx COVID-19 antigen test has received Emergency Use Authorization from the U.S. Food and Drug Administration and achieved CE Mark. The LumiraDx Platform and COVID-19 antigen tests are also available in Japan and Brazil and are being rolled out in more than 60 countries globally.
The Sidley team is being led by Alex Temel, Josh DuClos, David Ni, and Dan Rawner, and includes Jordan Baber, Albertina Kawatu, Garret Wade, and Kourosh Azin, as well as Patrick Harrison, Karen Kazmerzak, and Stewart Inman, Stacy Crosnicker, Peter McCorkell, Richard Schneider, Bethany Wise, Torrey Cope, Marie Manley, Diane McEnroe, Helen Middleton, Zina Chatzidimitiriadou, Rachael Hunt, Donielle McCutcheon, Kim Schroer, Francesca Blythe, Tom Cunningham, William Long, Lauren Kitces, Chris Brause, Rachel Kleinberg, Jonathan Westreich, Jennifer Coplan, Lauren Grau, Daphne Chen, Jim Ducayet, and Michael Mann.